ConductScience.org, home

Comparison · NCT03129321-68c4686b

Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure. Trial comparisons, record NCT03129321-68c4686b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03129321-68c4686b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5190.4470.59wilson
Risk in group 20.4760.4030.551wilson
Risk difference, group 1 minus group 20.0424-0.06110.145newcombe hybrid score
Risk ratio, group 1 over group 21.090.8831.34log
Odds ratio, group 1 over group 21.190.7811.8log
Number needed to treat, for one more participant with the outcome on Test than on Reference Standard23.6from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1TestEconazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days~Econazole Nitrate Cream, 1%96185OG000
Group 2Reference StandardEconazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days~Econazole Nitrate Cream, 1%81170OG001

Outcome

Type
PRIMARY
Title
Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure
Description
To be considered a Therapeutic Cure, the patient must have both Clinical Cure (patient's total severity score must be ≤ 2 with no individual severity score \> 1) and Mycological Cure (patient must have a negative KOH test and a negative fungal culture) of tinea pedis
Time frame
Day 42
Population
Active Treatments of the Per Protocol Population

Source ClinicalTrials.gov

Trial

Title
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
NCT number
NCT03129321
Phases
PHASE3
Conditions
Tinea Pedis
Interventions
Econazole Nitrate Cream, 1%, Placebo
Lead sponsor
Mylan Inc.
Results first posted
2018-08-02

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03129321-68c4686b